“Never, never, never give up.” ― Winston Churchill “Winners never quit and quitters never win.” – Vince Lombardi I’m sure we’ve all heard at least one of the above quotes. Well, I’m here to tell you the opposite. You should quit, sometimes. We have the tendency to keep working at things even though they are not working out or when there are better things we could be doing with our time. History is riddled with events that could have been…

The Rhodes Scholarship is the oldest (first awarded in 1902) and perhaps most prestigious international scholarship programme, enabling outstanding young people from around the world to study at the University of Oxford. The deadline for the application is 15th September,2021.To know more about the scholarship and the application requirements,vist the rhodes scholarship application page www.rhodeshouse.ox.ac.uk/apply

C.N: Welcome sir. It’s good to have you here. Can you kindly tell us about yourself? H.A: Hello, my name is Hassan Ademola Aderinto. I am a recent graduate of the University of Ibadan, where I studied Medical Laboratory Science. I hail from Oyo State and I reside in Lagos State, Nigeria. I am also the president of Junior Chamber International Nigeria, University College Hospital, Ibadan. C.N: Nice to meet you. Can you tell us a little about what your…

The head pastor of the Synagogue Church of All Nations, Prophet T.B. Joshua, was reported to have died on the 5th of June, 2021. The news about his death was updated on the Instagram account of the diseased prophet on the day of his demise.

The Chess competition that was organized by UIMSA was held on the 22nd of May, 2021. It was scheduled to start at 12: 30 pm. Each constituency under UIMSA was represented by those that their respective classes have deemed worthy or qualified to represent the class. Mr Oladotun Motolani and Mr Olaniran Oluwatosin, both of the 2k18 constituency emerged as winners of the competition. This was closely followed by the representatives of the 2k17 class. The results of the competition…

The United States has approved the first new treatment for Alzheimer’s disease for nearly 20 years. It was approved by regulators in the United States. Aducanumab targets the underlying cause of Alzheimer’s, the most common form of dementia rather than its symptoms. In March 2019, late-stage international trials of aducanumab, involving about 3,000 patients, were halted when analysis showed it was no better, given as a monthly infusion, at slowing the deterioration of memory and thinking problems than a dummy…